{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:38:44Z","timestamp":1789137524456,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"GSK","award":["212144, 201000"],"award-info":[{"award-number":["212144, 201000"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cholestatic pruritus is common in primary biliary cholangitis (PBC), often leading to sleep disturbances and substantially impairing health-related quality of life (HRQoL). Fatigue, also frequent in PBC, can be exacerbated by sleep interference due to nighttime pruritus. Quantitative numerical rating scales (NRS) are appropriate for assessing unidimensional patient-reported outcome (PRO) concepts and are easily interpreted. The PBC-40 is a disease-specific, patient-derived 40-item tool that assesses HRQoL in patients with PBC. To assess pruritus severity in clinical trials, rigorous validation of PROs in the target patient population is required. This study aimed to validate the NRS items for worst itch (WI-NRS), pruritus-related sleep interference (Sleep Interference NRS), and fatigue (Fatigue NRS), plus the PBC-40 (modified with a 7-day recall), among patients with PBC and pruritus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>Data were analyzed from the Phase 2b GLIMMER trial (NCT02966834) of linerixibat and a separate observational study in patients with PBC and pruritus. Pruritus severity was assessed using the 0\u201310 WI-NRS. Psychometric properties of the WI-NRS, Sleep Interference NRS, Fatigue NRS, and PBC-40 (7-day recall) were evaluated. Additional PRO data were used to support validation analyses. Multiple psychometric methods were used to validate the NRS items and PBC-40 (7-day recall).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Data for 288 patients (n=147 GLIMMER; n=141 observational study) with PBC experiencing pruritus were included. The internal consistency of PBC-40 (7-day recall) was acceptable to excellent and confirmatory factor analysis confirmed its domain structure. All PBC-40 domains showed acceptable test\u2013retest reliability (intraclass correlation coefficients [ICCs]: 0.72\u20130.90). The WI-NRS showed acceptable test\u2013retest reliability (ICCs: 0.73\u20130.81 [GLIMMER]; ICC: 0.78 [observational study]). Test\u2013retest reliability was also acceptable for the Sleep Interference (ICC: 0.85 [GLIMMER]; ICC: 0.77 [observational study]) and Fatigue (ICC: 0.88 [GLIMMER]; ICC: 0.78 [observational study]) NRS items. Convergent, discriminant, and known-groups validity were confirmed for all three NRS items and the PBC-40. Additionally, the NRS and PBC-40 Itch domain demonstrated responsiveness by reflecting change in other PROs over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The data support the psychometric reliability, validity, and responsiveness of WI-NRS, pruritus-related Sleep Interference NRS, and Fatigue NRS, and PBC-40 (7-day recall) in patients with PBC experiencing pruritus.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-03798-x","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T18:53:20Z","timestamp":1753988000000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Psychometric validation of the Worst Itch Numerical Rating Scale (WI-NRS) and other patient-reported outcome measures for assessing severity and impact of pruritus in patients with primary biliary cholangitis"],"prefix":"10.1186","volume":"20","author":[{"given":"Heather","family":"Gelhorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke M.","family":"Currie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald M.","family":"Bushnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona L.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatoumata","family":"Fofana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Karn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlyn J.","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan M.","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9058-8108","authenticated-orcid":false,"given":"Robyn","family":"von Maltzahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"3798_CR1","doi-asserted-by":"publisher","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145\u201372. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.022.","DOI":"10.1016\/j.jhep.2017.03.022"},{"issue":"7","key":"3798_CR2","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.cgh.2018.12.007","volume":"17","author":"VS Hegade","year":"2019","unstructured":"Hegade VS, Mells GF, Fisher H, Kendrick S, DiBello J, Gilchrist K, Alexander GJ, Hirschfield GM, Sandford RN, Jones DEJ, the UK-PBC Consortium. Pruritus is common and undertreated in patients with primary biliary cholangitis in the united Kingdom. Clin Gastroenterol Hepatol. 2019;17(7):1379\u20131387.E3. https:\/\/doi.org\/10.1016\/j.cgh.2018.12.007.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"3798_CR3","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s10620-022-07581-x","volume":"68","author":"MJ Mayo","year":"2023","unstructured":"Mayo MJ, Carey E, Smith HT, Mospan AR, McLaughlin M, Thompson A, Morris HL, Sandefur R, Kim WR, Bowlus C, the TARGET-PBC Investigators, Levy C. Impact of pruritus on quality of life and current treatment patterns in patients with primary biliary cholangitis. Dig Dis Sci. 2023;68(3):995\u20131005. https:\/\/doi.org\/10.1007\/s10620-022-07581-x.","journal-title":"Dig Dis Sci"},{"key":"3798_CR4","doi-asserted-by":"publisher","unstructured":"Pate J, Gutierrez JA, Frenette CT, Goel A, Kumar S, Manch RA, Mena EA, Pockros PJ, Satapathy SK, Yimam KK, Gish RG. Practical strategies for pruritus management in the obeticholic acid-treated patient with PBC: proceedings from the 2018 expert panel. BMJ Open Gastroenterol. 2019;6(1):e000256. https:\/\/doi.org\/10.1136\/bmjgast-2018-000256","DOI":"10.1136\/bmjgast-2018-000256"},{"issue":"3","key":"3798_CR5","doi-asserted-by":"publisher","first-page":"E252","DOI":"10.1111\/hepr.12978","volume":"48","author":"S Oeda","year":"2018","unstructured":"Oeda S, Takahashi H, Yoshida H, Ogawa Y, Imajo K, Yoneda M, Koshiyama Y, Ono M, Hyogo H, Kawaguchi T, Fujii H, Nishino K, Sumida Y, Tanaka S, Kawanaka M, Torimura T, Saibara T, Kawaguchi A, Nakajima A, Eguchi Y, Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Prevalence of pruritus in patients with chronic liver disease: a multicenter study. Hepatol Res. 2018;48(3):E252\u201362. https:\/\/doi.org\/10.1111\/hepr.12978","journal-title":"Hepatol Res"},{"key":"3798_CR6","doi-asserted-by":"publisher","unstructured":"Gungabissoon U, Smith HT, von Maltzahn R, Logie J, Fairburn-Beech J, Ma LPD, McGirr A, Hunnicutt JN, Rowe CL, Tierney M, Friedler HS. Pruritus in primary biliary cholangitis is under-recorded in patient medical records. BMJ Open Gastroenterol. 2024;11(1). https:\/\/doi.org\/10.1136\/bmjgast-2023-001287.","DOI":"10.1136\/bmjgast-2023-001287"},{"issue":"1","key":"3798_CR7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s41687-024-00722-y","volume":"8","author":"R von Maltzahn","year":"2024","unstructured":"von Maltzahn R, Mayo MJ, Smith HT, Thompson A, Das S, de Souza AR, Lisi E, Levy C, McLaughlin MM, Jones D. Relationship between pruritus and sleep in participants with primary biliary cholangitis in the phase 2b GLIMMER trial. J Patient Rep Outcomes. 2024;8(1):60. https:\/\/doi.org\/10.1186\/s41687-024-00722-y.","journal-title":"J Patient Rep Outcomes"},{"issue":"1","key":"3798_CR8","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/hep.30145","volume":"69","author":"KD Lindor","year":"2019","unstructured":"Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69(1):394\u2013419. https:\/\/doi.org\/10.1002\/hep.30145.","journal-title":"Hepatology"},{"issue":"1","key":"3798_CR9","doi-asserted-by":"publisher","first-page":"e0216","DOI":"10.1097\/CLD.0000000000000216","volume":"23","author":"A Faisal","year":"2024","unstructured":"Faisal A. Understanding fatigue and pruritus in primary biliary cholangitis. Clin Liver Dis (Hoboken). 2024;23(1):e0216. https:\/\/doi.org\/10.1097\/CLD.0000000000000216.","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"3798_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s41687-018-0056-3","volume":"2","author":"K Gries","year":"2017","unstructured":"Gries K, Berry P, Harrington M, Crescioni M, Patel M, Rudell K, Safikhani S, Pease S, Vernon M. Literature review to assemble the evidence for response scales used in patient-reported outcome measures. J Patient Rep Outcomes. 2017;2:41. https:\/\/doi.org\/10.1186\/s41687-018-0056-3.","journal-title":"J Patient Rep Outcomes"},{"issue":"9","key":"3798_CR11","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.ekir.2020.04.027","volume":"5","author":"HA Verduzco","year":"2020","unstructured":"Verduzco HA, Shirazian S. CKD-Associated pruritus: new insights into diagnosis, pathogenesis, and management. Kidney Int Rep. 2020;5(9):1387\u2013402. https:\/\/doi.org\/10.1016\/j.ekir.2020.04.027.","journal-title":"Kidney Int Rep"},{"issue":"4","key":"3798_CR12","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1007\/s12325-024-02802-3","volume":"41","author":"A Rams","year":"2024","unstructured":"Rams A, Baldasaro J, Bunod L, Delbecque L, Strzok S, Meunier J, ElMaraghy H, Sun L, Pierce E. Assessing itch severity: content validity and psychometric properties of a patient-reported Pruritus Numeric Rating Scale in atopic dermatitis. Adv Ther. 2024;41(4):1512\u201325. https:\/\/doi.org\/10.1007\/s12325-024-02802-3","journal-title":"Adv Ther"},{"issue":"4","key":"3798_CR13","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bjd.17744","volume":"181","author":"G Yosipovitch","year":"2019","unstructured":"Yosipovitch G, Reaney M, Mastey V, Eckert L, Abbe A, Nelson L, Clark M, Williams N, Chen Z, Ardeleanu M, Akinlade B, Graham NMH, Pirozzi G, Staudinger H, Plaum S, Radin A, Gadkari A. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181(4):761\u20139. https:\/\/doi.org\/10.1111\/bjd.17744.","journal-title":"Br J Dermatol"},{"issue":"8","key":"3798_CR14","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00403-020-02148-0","volume":"313","author":"SR Janmohamed","year":"2021","unstructured":"Janmohamed SR, Gwillim EC, Yousaf M, Patel KR, Silverberg JI. The impact of prurigo nodularis on quality of life: a systematic review and meta-analysis. Arch Dermatol Res. 2021;313(8):669\u201377. https:\/\/doi.org\/10.1007\/s00403-020-02148-0.","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"3798_CR15","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jid.2018.12.004","volume":"139","author":"S Erickson","year":"2019","unstructured":"Erickson S, Kim BS. Research techniques made simple: itch measurement in clinical trials. J Invest Dermatol. 2019;139(2):264\u20139. https:\/\/doi.org\/10.1016\/j.jid.2018.12.004. e261.","journal-title":"J Invest Dermatol"},{"key":"3798_CR16","unstructured":"Food and Drug Administration (FDA). Development of Non-Opioid Analgesics for Acute Pain. Guidance for Industry. 2022. Accessed August 8, 2024. https:\/\/www.fda.gov\/media\/156063\/download"},{"issue":"3","key":"3798_CR17","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.jval.2016.10.006","volume":"20","author":"A Gnanasakthy","year":"2017","unstructured":"Gnanasakthy A, Mordin M, Evans E, Doward L, DeMuro C. A review of patient-reported outcome labeling in the United States (2011\u20132015). Value Health. 2017;20(3):420\u20139. https:\/\/doi.org\/10.1016\/j.jval.2016.10.006","journal-title":"Value Health"},{"issue":"4","key":"3798_CR18","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.jval.2021.10.006","volume":"25","author":"A Gnanasakthy","year":"2022","unstructured":"Gnanasakthy A, Norcross L, DeMuro Romano C, Carson RT. A review of patient-reported outcome labeling of FDA-approved new drugs (2016\u20132020): counts, categories, and comprehensibility. Value Health. 2022;25(4):647\u201355. https:\/\/doi.org\/10.1016\/j.jval.2021.10.006","journal-title":"Value Health"},{"key":"3798_CR19","doi-asserted-by":"publisher","unstructured":"Levy C, Kendrick S, Bowlus CL, Tanaka A, Jones D, Kremer AE, Mayo MJ, Haque N, von Maltzahn R, Allinder M, Swift B, McLaughlin MM, Hirschfield GM, GLIMMER Study Group. GLIMMER: a randomized phase 2b dose-ranging trial of linerixibat in primary biliary cholangitis patients with pruritus. Clin Gastroenterol Hepatol. 2023;21(7):1902\u20131912.E13. https:\/\/doi.org\/10.1016\/j.cgh.2022.10.032","DOI":"10.1016\/j.cgh.2022.10.032"},{"key":"3798_CR20","doi-asserted-by":"publisher","unstructured":"Bowlus CL, Eksteen B, Cheung AC, Thorburn D, Moylan CA, Pockros PJ, Forman LM, Dorenbaum A, Hirschfield GM, Kennedy C, Jaecklin T, McKibben A, Chien E, Baek M, Vig P, Levy C. Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: open-label pilot study. Hepatol Commun. 2023;7(6):e0153. https:\/\/doi.org\/10.1097\/HC9.0000000000000153","DOI":"10.1097\/HC9.0000000000000153"},{"key":"3798_CR21","unstructured":"Foster B, Andrae D, Vig P, McKibben A, Bowlus C. Psychometric evaluation of the Adult Itch Reported Outcome tool, a worst itch numeric rating scale in adults with cholestatic liver disease. The Digital International Liver Congress\u2122 (Poster no. FRI131). 2020. https:\/\/mirumpharma.com\/wp-content\/uploads\/2021\/06\/b6ed837977fb-Adult_ItchRO_poster_EASL_2020_FINAL_14Jul20_SENT_TO_EOs.pdf"},{"key":"3798_CR22","doi-asserted-by":"publisher","first-page":"100107","DOI":"10.1016\/j.jtauto.2021.100107","volume":"4","author":"SC Gordon","year":"2021","unstructured":"Gordon SC, Trudeau S, Regev A, Uhas JM, Chakladar S, Pinto-Correia A, Gottlieb K, Schlichting D. Baricitinib and primary biliary cholangitis. J Transl Autoimmun. 2021;4:100107. https:\/\/doi.org\/10.1016\/j.jtauto.2021.100107.","journal-title":"J Transl Autoimmun"},{"issue":"10074","key":"3798_CR23","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/S0140-6736(17)30319-7","volume":"389","author":"VS Hegade","year":"2017","unstructured":"Hegade VS, Kendrick SF, Dobbins RL, Miller SR, Thompson D, Richards D, Storey J, Dukes GE, Corrigan M, Oude Elferink RP, Beuers U, Hirschfield GM, Jones DE. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet. 2017;389(10074):1114\u201323. https:\/\/doi.org\/10.1016\/S0140-6736(17)30319-7.","journal-title":"Lancet"},{"issue":"9","key":"3798_CR24","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJMoa2312100","volume":"390","author":"GM Hirschfield","year":"2024","unstructured":"Hirschfield GM, Bowlus CL, Mayo MJ, Kremer AE, Vierling JM, Kowdley KV, Levy C, Villamil A, Ladron de Guevara Cetina AL, Janczewska E, Zigmond E, Jeong SH, Yilmaz Y, Kallis Y, Corpechot C, Buggisch P, Invernizzi P, Londono Hurtado MC, Bergheanu S, Yang K, Choi YJ, Crittenden DB, McWherter CA, RESPONSE Study Group. A phase 3 trial of seladelpar in primary biliary cholangitis. N Engl J Med. 2024;390(9):783\u201394. https:\/\/doi.org\/10.1056\/NEJMoa2312100","journal-title":"N Engl J Med"},{"issue":"2","key":"3798_CR25","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/hep.0000000000000395","volume":"78","author":"GM Hirschfield","year":"2023","unstructured":"Hirschfield GM, Shiffman ML, Gulamhusein A, Kowdley KV, Vierling JM, Levy C, Kremer AE, Zigmond E, Andreone P, Gordon SC, Bowlus CL, Lawitz EJ, Aspinall RJ, Pratt DS, Raikhelson K, Gonzalez-Huezo MS, Heneghan MA, Jeong SH, Ladr\u00f3n de Guevara AL, Mayo MJ, Dalekos GN, Drenth JPH, Janczewska E, Leggett BA, Nevens F, Vargas V, Zuckerman E, Corpechot C, Fassio E, Hinrichsen H, Invernizzi P, Trivedi PJ, Forman L, Jones DEJ, Ryder SD, Swain MG, Steinberg A, Boudes PF, Choi YJ, McWherter CA. Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study. Hepatology. 2023;78(2):397\u2013415. https:\/\/doi.org\/10.1097\/hep.0000000000000395.","journal-title":"Hepatology"},{"issue":"9","key":"3798_CR26","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2306185","volume":"390","author":"KV Kowdley","year":"2024","unstructured":"Kowdley KV, Bowlus CL, Levy C, Akarca US, Alvares-da-Silva MR, Andreone P, Arrese M, Corpechot C, Francque SM, Heneghan MA, Invernizzi P, Jones D, Kruger FC, Lawitz E, Mayo MJ, Shiffman ML, Swain MG, Valera JM, Vargas V, Vierling JM, Villamil A, Addy C, Dietrich J, Germain JM, Mazain S, Rafailovic D, Tadde B, Miller B, Shu J, Zein CO, Schattenberg JM, ELATIVE Study Investigators\u2019 Group. Efficacy and safety of elafibranor in primary biliary cholangitis. N Engl J Med. 2024;390(9):795\u2013805. https:\/\/doi.org\/10.1056\/NEJMoa2306185.","journal-title":"N Engl J Med"},{"issue":"3","key":"3798_CR27","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/hep4.1305","volume":"3","author":"MJ Mayo","year":"2019","unstructured":"Mayo MJ, Pockros PJ, Jones D, Bowlus CL, Levy C, Patanwala I, Bacon B, Luketic V, Vuppalanchi R, Medendorp S, Dorenbaum A, Kennedy C, Novak P, Gu J, Apostol G, Hirschfield GM. A randomized, controlled, phase 2 study of maralixibat in the treatment of itching associated with primary biliary cholangitis. Hepatol Commun. 2019;3(3):365\u201381. https:\/\/doi.org\/10.1002\/hep4.1305.","journal-title":"Hepatol Commun"},{"issue":"3","key":"3798_CR28","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.1526-4637.2009.00774.x","volume":"11","author":"TM Atkinson","year":"2010","unstructured":"Atkinson TM, Mendoza TR, Sit L, Passik S, Scher HI, Cleeland C, Basch E. The brief pain inventory and its \u201cpain at its worst in the last 24 hours\u201d item: clinical trial endpoint considerations. Pain Med. 2010;11(3):337\u201346. https:\/\/doi.org\/10.1111\/j.1526-4637.2009.00774.x.","journal-title":"Pain Med"},{"issue":"11","key":"3798_CR29","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1136\/gut.2005.065862","volume":"54","author":"A Jacoby","year":"2005","unstructured":"Jacoby A, Rannard A, Buck D, Bhala N, Newton JL, James OF, Jones DE. Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis. Gut. 2005;54(11):1622\u20139. https:\/\/doi.org\/10.1136\/gut.2005.065862.","journal-title":"Gut"},{"issue":"1","key":"3798_CR30","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s41687-018-0090-1","volume":"3","author":"ML Martin","year":"2019","unstructured":"Martin ML, Stassek L, Blum SI, Joshi AV, Jones D. Development and adaptation of patient-reported outcome measures for patients who experience itch associated with primary biliary cholangitis. J Patient Rep Outcomes. 2019;3(1):2. https:\/\/doi.org\/10.1186\/s41687-018-0090-1.","journal-title":"J Patient Rep Outcomes"},{"key":"3798_CR31","doi-asserted-by":"publisher","unstructured":"de Veer RC, da Silva G, van Hooff MC, Harms MH, Metselaar HJ, Willemse J, Utomo E, van der Meer AJ. Measurement properties of the PBC-40 and PBC-27: a Dutch validation study. BMJ Open Gastroenterol. 2021;8(1):e000758. https:\/\/doi.org\/10.1136\/bmjgast-2021-000758.","DOI":"10.1136\/bmjgast-2021-000758"},{"issue":"3","key":"3798_CR32","doi-asserted-by":"publisher","first-page":"e0057","DOI":"10.1097\/HC9.0000000000000057","volume":"7","author":"D Jones","year":"2023","unstructured":"Jones D, Carbone M, Invernizzi P, Little N, Nevens F, Swain MG, Wiesel P, Levy C. Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial. Hepatol Commun. 2023;7(3):e0057. https:\/\/doi.org\/10.1097\/HC9.0000000000000057.","journal-title":"Hepatol Commun"},{"issue":"1","key":"3798_CR33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/1751-2980.13254","volume":"25","author":"YS Liu","year":"2024","unstructured":"Liu YS, Jia G, Ding DW, Zheng LH, Sun RQ, Wang XF, Deng J, Yang CM, Cui LN, Guo CC, Shang YL, Han Y. Differences in the perceptions of patients with primary biliary cholangitis and physicians from various hospital departments: an online survey. J Dig Dis. 2024;25(1):61\u20139. https:\/\/doi.org\/10.1111\/1751-2980.13254.","journal-title":"J Dig Dis"},{"issue":"3","key":"3798_CR34","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/j.1365-2133.2009.09586.x","volume":"162","author":"S Elman","year":"2010","unstructured":"Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D itch scale: a new measure of pruritus. Br J Dermatol. 2010;162(3):587\u201393. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09586.x.","journal-title":"Br J Dermatol"},{"issue":"5","key":"3798_CR35","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol group. Ann Med. 2001;33(5):337\u201343. https:\/\/doi.org\/10.3109\/07853890109002087.","journal-title":"Ann Med"},{"key":"3798_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780198527695.003.0003","volume-title":"Reliability and validity (including responsiveness)","author":"R Hays","year":"2005","unstructured":"Hays R, Revicki DA. Reliability and validity (including responsiveness). New York: Oxford University Press; 2005."},{"key":"3798_CR37","unstructured":"Yu C. (2002) Evaluating cutoff criteria of model fit indices for latent variable models with binary and continuous outcomes [Doctoral Dissertation]. University of California, Los Angeles."},{"issue":"5","key":"3798_CR38","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.paid.2006.09.017","volume":"42","author":"J Steiger","year":"2007","unstructured":"Steiger J. Understanding the limitations of global fit assessment in structural equation modeling. Pers Individ Dif. 2007;42(5):893\u20138. https:\/\/doi.org\/10.1016\/j.paid.2006.09.017.","journal-title":"Pers Indiv Differ"},{"issue":"1","key":"3798_CR39","first-page":"53","volume":"6","author":"DCJ Hooper","year":"2008","unstructured":"Hooper D, Coughlan J, Mullen M. Structural equation modelling: guidelines for determining model fit. Electron J Bus Res Methods. 2008;6(1):53\u201360.","journal-title":"Electron J Bus Res Methods"},{"issue":"2","key":"3798_CR40","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/bjd.20783","volume":"186","author":"J Puelles","year":"2022","unstructured":"Puelles J, Fofana F, Rodriguez D, Silverberg JI, Wollenberg A, Dias Barbosa C, Vernon M, Chavda R, Gabriel S, Piketty C. Psychometric validation and responder definition of the sleep disturbance numerical rating scale in moderate-to-severe atopic dermatitis. Br J Dermatol. 2022;186(2):285\u201394. https:\/\/doi.org\/10.1111\/bjd.20783.","journal-title":"Br J Dermatol"},{"issue":"1","key":"3798_CR41","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12955-021-01877-8","volume":"19","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, DeLozier A, Sun L, Thyssen JP, Kim B, Yosipovitch G, Nunes FP, Gugiu PC, Doll HA, Eichenfield LF. Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis. Health Qual Life Outcomes. 2021;19(1):247. https:\/\/doi.org\/10.1186\/s12955-021-01877-8.","journal-title":"Health Qual Life Outcomes"},{"issue":"12","key":"3798_CR42","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1001\/jamadermatol.2020.3071","volume":"156","author":"M Kimel","year":"2020","unstructured":"Kimel M, Zeidler C, Kwon P, Revicki D, Stander S. Validation of psychometric properties of the itch numeric rating scale for pruritus associated with prurigo nodularis: a secondary analysis of a randomized clinical trial. JAMA Dermatol. 2020;156(12):1354\u20138. https:\/\/doi.org\/10.1001\/jamadermatol.2020.3071","journal-title":"JAMA Dermatol"},{"issue":"1","key":"3798_CR43","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s41687-021-00404-z","volume":"5","author":"MK Vernon","year":"2021","unstructured":"Vernon MK, Swett LL, Speck RM, Munera C, Spencer RH, Wen W, Menzaghi F. Psychometric validation and meaningful change thresholds of the Worst Itching Intensity Numerical Rating Scale for assessing itch in patients with chronic kidney disease-associated pruritus. J Patient Rep Outcomes. 2021;5(1):134. https:\/\/doi.org\/10.1186\/s41687-021-00404-z.","journal-title":"J Patient Rep Outcomes"},{"key":"3798_CR44","unstructured":"ClinicalTrials.gov. Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN). Identifier NCT04950127. https:\/\/clinicaltrials.gov\/study\/NCT04950127?term=NCT04950127&rank=1 Accessed March 12, 2025."},{"key":"3798_CR45","unstructured":"ClinicalTrials.gov. Linerixibat Long-term Safety, and Tolerability Study (LLSAT). Identifier NCT04167358. https:\/\/clinicaltrials.gov\/study\/NCT04167358?term=NCT04167358&rank=1 Accessed October 17, 2024."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03798-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03798-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03798-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T09:53:58Z","timestamp":1757325238000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03798-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3798"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03798-x","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"assertion":[{"value":"24 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Both the GLIMMER and observational study protocol were reviewed and approved by an ethics committee or institutional review board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"As part of the study participation consent, participants provided written consent for their anonymized data to be published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BMC, MMM, and RvM are employed by GSK and hold financial equities in GSK. HG, DMB, MLM, FF, and HK are employees of Evidera, who was funded by GSK to carry out the observational study and psychometric analyses using the GLIMMER data. MJM has received research support from CymaBay, GSK, Intercept, Ipsen, Mallinckrodt and Mirum, and has consulted for CymaBay, GSK, and Mallinckrodt. DEJ has received grant funding or fees from Abbott, Falk, GSK, Intercept, Novartis, and Pfizer. Study conduct and data analysis were performed by Evidera funded by GSK. No funding was provided to Evidera for manuscript development.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"390"}}